STOCK TITAN
  1. Home
  2. News
  3. AXGN

Axogen Inc. - AXGN STOCK NEWS

Welcome to our dedicated news page for Axogen (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Axogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Axogen's position in the market.

News
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Rhea-AI Summary
Axogen, Inc. will report its first quarter 2024 financial results on May 2, 2024, followed by an investment-community conference call and webcast. Investors can participate via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences earnings
-
News
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
Rhea-AI Summary
Axogen, Inc. (AXGN) reports strong financial results for Q4 2023 and full-year 2023 with revenue growth, net loss reduction, and new product launches. The company's revenue increased to $42.9 million in Q4, representing an 18.7% growth from 2022. Full-year revenue reached $159.0 million, a 14.7% increase from 2022. Axogen aims for further growth with the launch of Avive+ Soft Tissue Matrix in Q2 2024 and expects revenue between $177 million to $181 million for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.11%
Tags
earnings
-
News
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN) will report its 2023 fourth quarter and full-year financial results on March 5, 2024. The company specializes in innovative surgical solutions for peripheral nerve injuries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
conferences earnings
News
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN) announced the induction of John Manning as the Area Vice President of Sales and the granting of equity awards as an inducement for his employment. The equity grant consists of non-qualified stock options to purchase 18,700 shares of the company’s common stock and non-qualified restricted stock units representing 10,000 shares of the company’s common stock. The stock options have an exercise price of $9.75 per share and will vest over a four-year period, while the RSUs are subject to vesting over 4 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
Rhea-AI Summary
Axogen, Inc. (AXGN) announced positive results from its REPOSE clinical study, demonstrating the statistical superiority of Axoguard Nerve Cap over standard-of-care neurectomy in reducing pain for patients with symptomatic neuroma. The study met its primary endpoint for pain reduction, with the Axoguard Nerve Cap group showing superior results compared to the standard-of-care neurectomy group over the 12-month follow-up period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.86%
Tags
clinical trial
-
News
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
Rhea-AI Summary
Axogen, a global leader in surgical solutions for peripheral nerve injuries, announced preliminary unaudited fourth quarter and full-year 2023 revenue. Fourth-quarter revenue is expected to be $42.7 million, representing an 18% increase over 2022. Full-year 2023 revenue is expected to be $158.8 million, a 15% increase over 2022. Core Accounts are expected to represent 65% of revenue for 2023, with 375 accounts at the end of the fourth quarter. The company achieved a milestone of surpassing 100,000 Avance Nerve Graft implants since its launch. Axogen also introduced Axoguard HA+ Nerve Protector and plans to roll out Avive+ Soft Tissue Matrix in 2024. The company expects to be cash flow positive and profitable in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.67%
Tags
none
News
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
Rhea-AI Summary
Axogen, a global leader in surgical solutions for peripheral nerve injuries, announced the retirement of President and CEO Karen Zaderej by January 2025. The Board will search for her successor and Ms. Zaderej will continue as a consultant for nine months. The company reported 2023 revenue of $158.8 million, with 15% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.67%
Tags
management
-
News
Axogen Announces Promotions on Research and Development Team
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN) announces the promotions of three research and development team members and the departure of Angelo Scopelianos, Ph.D. The promotions include Erick DeVinney to Chief Innovation Officer, Ivica Ducic, M.D., Ph.D., to Chief Medical Officer, and Stacy Arnold to Vice President of Product Development and Clinical Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.67%
Tags
management
-
News
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN) appoints Kathy Weiler, a senior executive with 20+ years of experience, to its Board of Directors. Weiler brings her extensive commercial experience to support Axogen's patient activation and commercial execution as the company drives toward being cash flow positive.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
management
News
Axogen Announces Transition of Finance Team Leadership
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN) appoints Nir Naor as CFO, replacing Peter Mariani. Naor brings over 20 years of experience in life sciences finance. The move aligns with the company's focus on revenue growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
none
Stock AXGN logo
Axogen Inc.

Nasdaq:AXGN

AXGN Rankings

#3448 Ranked by Market Cap
#5079 Ranked by Stock Gains
N/A Ranked by Dividends

AXGN Stock Data

305.81M
33.46M
5.05%
77.22%
3.95%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Alachua

About AXGN

it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.